Neuland Laboratories Limited has informed the Exchange about Transcript
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Labs reported a sharp Q1FY26 slowdown with total income of Rs. 300.6 crores, down 32.4% year-on-year from Rs. 444 crores. EBITDA came in at Rs. 42.1 crores (14.4% margin) and PAT fell to Rs. 13.7 crores from Rs. 98.3 crores a year ago, with EPS of Rs. 10.7. The weakness was driven by lumpy order flow in the CDMO and specialty businesses, leading to working capital of 145 days and negative free cash flow of Rs. 66 crores. The company remains net cash at Rs. 165 crores and plans Rs. 250 crores of FY26 capex (60% growth, 40% maintenance). Management reaffirmed its FY26 growth guidance on the FY24 base, expects another CMS molecule to commercialize this year, and sees the new Unit 3 production block contributing in H2FY26, while the peptide facility is on track for completion in the next financial year.
The sharp revenue and earnings decline reinforces the company's lumpy business profile and is likely to weigh on short-term sentiment, but management's reiteration of FY26 recovery driven by the Unit 3 ramp, new CMS molecule launch, and peptide pipeline provides a medium-term growth story. Net cash balance sheet and steady capex spending reduce near-term solvency concerns for shareholders.